Showing results (71-80 of 162) with videos related to
Sort By:
Pageof 17
Blood|March 24, 2018
Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphomaElena Battistello, Natalya Katanayeva, Elie Dheilly, et al.Nature Genetics|November 22, 2016
Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex biasAndrew Dunford, David M Weinstock, Virginia Savova, et al.Cancer Research|June 13, 2012
BCL2 suppresses PARP1 function and nonapoptotic cell deathChaitali Dutta, Tovah Day, Nadja Kopp, et al.Blood|August 10, 2018
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomasIrene Scarfò, Maria Ormhøj, Matthew J Frigault, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic LeukemiaYana Pikman, Gabriela Alexe, Giovanni Roti, et al.Journal of Hematology & Oncology|July 18, 2020
DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomasYonghan He, Raphael Koch, Vivekananda Budamagunta, et al.Blood|April 10, 2013
PARP1 is required for chromosomal translocationsJustin Wray, Elizabeth A Williamson, Sudha B Singh, et al.Nature Communications|June 14, 2017
Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNATovah A Day, Jacob V Layer, J Patrick Cleary, et al.Nature Communications|April 28, 2017
PARP3 is a promoter of chromosomal rearrangements and limits G4 DNATovah A Day, Jacob V Layer, J Patrick Cleary, et al.Blood Advances|January 4, 2018
Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunitiesElizabeth A Morgan, M Patrick Sweeney, Tamiwe Tomoka, et al.Pageof 17